NEW YORK, May 1, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Canntab Therapeutics Ltd (CSE: PILL; OTCQX: CTABF), a Canadian cannabis oral dosage formulation company engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has qualified to trade on the OTCQX® Best Market. Canntab Therapeutics upgraded to OTCQX from the OTCQB® Venture Market.
Canntab Therapeutics begins trading today on OTCQX under the symbol "CTBAF." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Canntab Therapeutics joins the OTCQX Best Market, trading alongside over 45 other cannabis companies that are innovators in the industry," said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. "Cross-trading on OTCQX provides Canntab Therapeutics' U.S. investors with greater access to the company's financials, news and research reports. We look forward to supporting Canntab Therapeutics as it expands its footprint in the U.S."
"Historically, it's been difficult for U.S. investors to take ownership of our company, that changes with our upgrade to the OTCQX Best Market. This move also coincides with Canntab reaching a major milestone in April which has opened the door for Canadian and international sales and white labeling," says Richard Goldstein, Chief Financial Officer of Canntab. Jeff Renwick, Chief Executive Officer and a Director of Canntab, further explains that "ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary process."
About Canntab Therapeutics Ltd.
Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.
OTC Markets Group Inc., +1 (212) 896-4428, firstname.lastname@example.org